CDw75/ST6GAL1 Antibody (0.N.161): sc-59147
- CDw75/ST6GAL1 Antibody (0.N.161) is a mouse monoclonal IgM provided at 200 µg/ml
- raised against pokeweed mitogen stimulated peripheral mononuclear cells
- recommended for detection of CDw75 of mouse, rat and human origin by IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CDw75/ST6GAL1 Antibody (0.N.161). This work is in progress.
QUICK LINKS
SEE ALSO...
ST6GAL1 Antibody (0.N.161) is a mouse monoclonal IgM antibody that detects ST6GAL1 in mouse, rat, and human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). ST6GAL1, also known as CD75, is a type II membrane protein predominantly expressed in the Golgi apparatus, where ST6GAL1 plays a crucial role in the biosynthesis of sialylated glycoproteins and glycolipids. ST6GAL1 is essential for generating specific cell surface antigens, including CDw75, which are important for cell-cell interactions and immune responses. CDw75 expression on B and T cells is particularly significant, as CDw75 may be upregulated in various hematological malignancies, including B-cell leukemias, indicating a potential role in tumorigenesis and immune evasion. Through facilitating sialic acid transfer to carbohydrate acceptors on the cell surface, ST6GAL1 contributes to immune signaling modulation and tumor-associated antigen development, making ST6GAL1 a valuable target for research in cancer biology and immunology. With insights into glycosylation patterns that influence cell behavior, anti-ST6GAL1 antibody (0.N.161) serves as an essential tool for researchers investigating cell surface modifications and their implications in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CDw75/ST6GAL1 Antibody (0.N.161) References:
- Epigenetic inactivation of ST6GAL1 in human bladder cancer. | Antony, P., et al. 2014. BMC Cancer. 14: 901. PMID: 25465919
- The role of DNA methylation in ST6Gal1 expression in gliomas. | Kroes, RA. and Moskal, JR. 2016. Glycobiology. 26: 1271-1283. PMID: 27510958
- Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer. | Wichert, B., et al. 2018. Glycobiology. 28: 898-903. PMID: 30016515
- The sialyltransferase ST6GAL1 protects against radiation-induced gastrointestinal damage. | Punch, PR., et al. 2020. Glycobiology. 30: 446-453. PMID: 31897489
- Blood-Borne ST6GAL1 Regulates Immunoglobulin Production in B Cells. | Irons, EE., et al. 2020. Front Immunol. 11: 617. PMID: 32391003
- ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab. | Duarte, HO., et al. 2021. Oncogene. 40: 3719-3733. PMID: 33947960
- ST6GAL1 and α2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease. | Krick, S., et al. 2021. Front Immunol. 12: 693149. PMID: 34290711
- Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia. | Zhang, M., et al. 2022. Front Oncol. 12: 828041. PMID: 35371997
- Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. | Watts, K., et al. 2022. Int J Cancer. 151: 957-966. PMID: 35467766
- N-linked α2,6-sialylation of integrin β1 by the sialyltransferase ST6Gal1 promotes cell proliferation and stemness in gestational trophoblastic disease. | Liu, J., et al. 2024. Placenta. 149: 18-28. PMID: 38490094
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CDw75/ST6GAL1 Antibody (0.N.161) | sc-59147 | 200 µg/ml | $322.00 |